Trial Profile
ECOG E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
- Indications Anal cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Primary endpoint (Local Failure Rate at 3 Years) has been met, according to results published in the Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- 09 Jan 2017 Results published in the Journal of clinical oncology : official journal of the American Society of Clinical Oncology.